SG Americas Securities LLC Makes New Investment in Caribou Biosciences, Inc. (NASDAQ:CRBU)

SG Americas Securities LLC acquired a new position in Caribou Biosciences, Inc. (NASDAQ:CRBU) in the 4th quarter, Holdings Channel reports. The firm acquired 39,577 shares of the company’s stock, valued at approximately $227,000.

Several other institutional investors have also added to or reduced their stakes in the stock. Thrive Wealth Management LLC bought a new position in Caribou Biosciences in the 4th quarter worth $183,000. Exchange Traded Concepts LLC increased its stake in shares of Caribou Biosciences by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 23,924 shares of the company’s stock worth $137,000 after acquiring an additional 6,066 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Caribou Biosciences by 49.3% in the 3rd quarter. Vanguard Group Inc. now owns 3,822,151 shares of the company’s stock worth $18,270,000 after acquiring an additional 1,261,920 shares in the last quarter. Citigroup Inc. increased its stake in shares of Caribou Biosciences by 739.3% in the 3rd quarter. Citigroup Inc. now owns 221,166 shares of the company’s stock worth $1,057,000 after acquiring an additional 194,816 shares in the last quarter. Finally, Wellington Management Group LLP bought a new position in shares of Caribou Biosciences in the 3rd quarter worth about $952,000. 77.51% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright increased their price target on shares of Caribou Biosciences from $23.00 to $24.00 and gave the stock a “buy” rating in a research note on Tuesday, March 19th.

Caribou Biosciences Stock Performance

Shares of CRBU stock opened at $4.33 on Friday. Caribou Biosciences, Inc. has a one year low of $3.44 and a one year high of $8.59. The company’s 50-day moving average is $6.16 and its 200 day moving average is $5.47. The company has a market capitalization of $391.09 million, a price-to-earnings ratio of -2.99 and a beta of 2.47.

Caribou Biosciences (NASDAQ:CRBU) last announced its quarterly earnings data on Monday, March 11th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.17). Caribou Biosciences had a negative net margin of 296.05% and a negative return on equity of 31.06%. The firm had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $5.17 million. As a group, research analysts predict that Caribou Biosciences, Inc. will post -1.76 earnings per share for the current fiscal year.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.